Cara Fraley
About Cara Fraley
Cara Fraley is a Research Scientist I at the Broad Institute of MIT and Harvard, where she has worked since 2018. With over 15 years of experience in protein expression and molecular biology, she contributes to projects in cardiovascular disease and oncology.
Work at Broad Institute
Since 2018, Cara Fraley has served as a Research Scientist I at the Broad Institute of MIT and Harvard in Cambridge, MA. In this role, she contributes to projects that focus on cardiovascular disease and oncology, utilizing her skills in protein production and characterization. Prior to her current position, she worked at the Broad Institute as a Senior Research Associate II from 2012 to 2018, where she further developed her expertise in protein expression and purification.
Previous Employment at Biogen Idec
Cara Fraley has held multiple positions at Biogen Idec. She worked as an Associate Scientist III from 2007 to 2010, followed by a role as Senior Associate Scientist from 2010 to 2012. During her time at Biogen Idec, she gained valuable experience in molecular biology and in vitro assay development, which contributed to her professional growth in the field of research.
Educational Background
Cara Fraley earned her Master of Science in Biochemistry from Boston College, where she studied from 1996 to 1999. Prior to that, she completed her Bachelor of Science in Chemistry at Seton Hall University from 1992 to 1996. Her educational background has provided a strong foundation for her extensive career in scientific research.
Experience and Expertise
With over 15 years of experience in the field, Cara Fraley specializes in protein expression, purification, and characterization. She possesses expertise in cell culture techniques, which she applies to discovery and pre-clinical development. Her diverse skill set supports her contributions to significant research projects in the biomedical sector.
Career Development at Syntonix Pharmaceuticals
Before her tenure at Biogen Idec, Cara Fraley worked as a Research Associate II at Syntonix Pharmaceuticals from 2001 to 2002. This early experience helped her build a solid foundation in research methodologies and techniques that she has continued to develop throughout her career.